We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Helix BioPharma Receives FDA IND Approval to Conduct a U.S. Phase I Clinical Study With L-DOS47

News   Feb 08, 2011

 
Helix BioPharma Receives FDA IND Approval to Conduct a U.S. Phase I Clinical Study With L-DOS47
 
 
 

RELATED ARTICLES

Vaccine Strategy Boosts T-Cell Therapy

News

In a study of mice, the researchers found that they could completely eliminate solid tumors in 60 percent of the animals that were given T-cell therapy along with the booster vaccination. Engineered T cells on their own had almost no effect.

READ MORE

RESCUE Fills a Critical Gap in the CRISPR Toolbox

News

Scientists have made use of a deactivated Cas13 to guide NA Editing for Specific C to U Exchange (RESCUE) to targeted cytosine bases on RNA transcripts, and used a novel, evolved, programmable enzyme to convert unwanted cytosine into uridine -- thereby directing a change in the RNA instructions.

READ MORE

Preventing Protein From “Doing Its Job” Could Stop Ovarian Cancer Cells From Spreading

News

By preventing a protein from doing its job, researchers discovered that it may be possible to keep a certain type of ovarian cancer cell from growing and dividing uncontrollably.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE